TRVI vs. MLTX, IMVT, HCM, AMRX, OGN, MIRM, APLS, DNLI, VCEL, and NAMS
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include MoonLake Immunotherapeutics (MLTX), Immunovant (IMVT), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), Denali Therapeutics (DNLI), Vericel (VCEL), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.
Trevi Therapeutics vs.
Trevi Therapeutics (NASDAQ:TRVI) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, community ranking, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.
MoonLake Immunotherapeutics' return on equity of -15.54% beat Trevi Therapeutics' return on equity.
MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.
95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Trevi Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
Trevi Therapeutics currently has a consensus price target of $17.56, suggesting a potential upside of 182.13%. MoonLake Immunotherapeutics has a consensus price target of $78.71, suggesting a potential upside of 102.53%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Trevi Therapeutics is more favorable than MoonLake Immunotherapeutics.
In the previous week, MoonLake Immunotherapeutics had 22 more articles in the media than Trevi Therapeutics. MarketBeat recorded 28 mentions for MoonLake Immunotherapeutics and 6 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.12 beat MoonLake Immunotherapeutics' score of 1.06 indicating that Trevi Therapeutics is being referred to more favorably in the media.
Trevi Therapeutics received 35 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 82.76% of users gave MoonLake Immunotherapeutics an outperform vote while only 68.15% of users gave Trevi Therapeutics an outperform vote.
Summary
Trevi Therapeutics beats MoonLake Immunotherapeutics on 10 of the 16 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TRVI) was last updated on 5/22/2025 by MarketBeat.com Staff
